The Centers for Medicare & Medicaid Services (CMS) has extended the deadline for Merit-based Incentive Payment System (MIPS) participants to report 2019 data within the Quality Payment Program (QPP) to April 30, 2020 due to the COVID-19 pandemic. The deadline had been March 31, 2020.
ASCO in Action provides the latest news and analysis related to critical policy issues affecting the cancer community, updates on the Association for Clinical Oncology’s ongoing advocacy efforts, and opportunities for members and others in the cancer care community to take action.
To sign up for advocacy alerts, log in to ASCO.org with your member or guest account, and visit the subscription center available under your account profile.
On March 18, the President signed into law the second emergency supplemental package designed to respond to COVID-19, which requires private health plans, Medicare Advantage Plans, TRICARE, veterans’ plans, federal workers' health plans, and the Indian Health Service to cover the COVID-19 diagnostic test at no cost to the patient and without prior authorization, as long as the patient visits a health care provider, urgent care center, or emergency room before receiving the test.
The Association for Clinical Oncology (ASCO) recently submitted comments in response to Part II of the Centers for Medicare & Medicaid Services’ (CMS) calendar year 2021 Advance Notice of Methodological Changes for Medicare Advantage Capitation Rates and Part C and Part D Payment Policies. The advance notice proposes updates and changes to the methodologies used to pay Medicare Advantage plans, Programs of All-Inclusive Care for the Elderly organizations, and Part D sponsors.
On March 6, 2020, President Trump signed into law the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020. On January 31, 2020, Health and Human Services (HHS) Secretary Azar declared a public health emergency effective January 27, 2020, affording the Centers for Medicare & Medicaid Services (CMS) the flexibility to quickly support Medicare beneficiaries.
The meetings focused on drug pricing, access to clinical trials, Medicaid expansion and block grants, accelerated drug approval pathways, and other issues affecting people with cancer and their oncology care teams.
“The American Society of Clinical Oncology (ASCO) applauds the Centers for Medicare & Medicaid Services (CMS) for reflecting recommendations in the Society’s position statement on pharmacy benefit managers (PBMs) in the agency’s 2021 and 2022 Medicare Advantage and Part D proposed rule.
The Centers for Medicare & Medicaid Services (CMS) announced important updates for 2019 and 2020 Merit-based Incentive Payment System (MIPS) participants, including the 2019 data submission period for MIPS eligible clinicians and how participants can check their 2020 MIPS eligibility.